Stingray Therapeutics
Restoring Innate Immunity against Cancer
Jonathan Northrup, Co-founder and CEO
Top Immune Oncology Companies 2026
Immune oncology companies develop therapies that help the immune system recognize and respond to cancer. With a focus on therapeutic research, clinical validation, patient safety and treatment precision, they support stronger oncology pipelines and more advanced cancer care.
Solutions
Stingray Therapeutics is developing Vizenpistat (SR-8541A) around a gap in cancer immunotherapy. Cancer treatment spans chemotherapy, targeted therapy, radiation, surgery and immune therapy, but each has limits. Stingray focuses on the immune system, which can recognize and eliminate cancer but can be disabled once tumors establish themselves.
State of Industry
Immune Oncology: Cancer Care through Precision Immunotherapy and Scientific Innovation
Immune oncology therapies boost or modify immune responses to better recognize the cancer and also help to control the disease for the long term. This approach has broadened treatment options for multiple types of cancer and continues to spur innovation in research, drug development, diagnostics and personalized healthcare. Immune oncology encompasses a variety of treatment strategies, including immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, cytokine therapies, oncolytic viruses, monoclonal antibodies and combination treatment strategies.
Deep Dive
Assessing Immune Oncology Companies Beyond Checkpoint Promise
Cancer immunotherapy selection increasingly turns on a biological constraint that standard checkpoint approaches do not always solve. Many tumors suppress the innate immune response that helps initiate interferon signaling and recruit adaptive immunity into the tumor environment. For executives assessing an immune oncology company, the central concern is not simply whether a program activates immune pathways. The mechanism must address a defined source of immune escape while preserving enough tolerability to support combination use.
Leadership Perspective
the Janssen Pharmaceutical Companies of Johnson & Johnson
The Cancer Immunotherapy Treatment Paradigm
Charles G. Drake, M.D., Ph.D., Vice President, Immuno-Oncology
Please comment on your current role and responsibility in leading the cancer immunotherapy research and development at Janssen?
I lead the immuno-oncology team at Janssen where our efforts are focused on the discovery and development of next-generation approaches to immunotherapy that include antibody-based drugs, cell therapies, and novel cancer vaccines.
Immune Oncology Companies Info
Q1
What Do Top Immune Oncology Companies Contribute to Cancer Treatment?
Immune oncology research explores ways to help the body's defenses recognize and attack cancer cells. Treatments in this field include immune checkpoint inhibitors, therapeutic vaccines, cell-based therapies, antibodies and drugs designed to change the tumor environment. Each approach targets a different part of the relationship between cancer and the immune system. Some treatments help immune cells identify malignant cells, while others aim to overcome mechanisms that allow tumors to escape detection. For Top Immune Oncology Companies, progress depends on understanding tumor biology and testing whether promising findings can translate into safe, effective treatments.
Q2
Which Organization Did Life Sciences Review Recognize for Immune Oncology in 2026?
Life Sciences Review recognized Stingray Therapeutics as the Most Innovative and Promising Immune Oncology Company in 2026. Its research focuses on innate immunity, a part of the body's defense system that may help the immune system respond to cancer. The company's work examines how tumors suppress immune activity and whether restoring those responses could complement existing treatments. This research represents one approach within immune oncology, where scientists continue to investigate why some cancers resist established therapies and how different immune pathways might be used to address that problem.
Q3
Why Is Demand for Immune Oncology Research Continuing to Grow?
Researchers are exploring new treatment options for cancers that respond poorly to existing medicines or have limited therapeutic choices. Top Immune Oncology Companies work in a field where tumors can suppress immune activity through different biological mechanisms, making consistent treatment responses difficult to achieve. Interest in new immune targets, combination therapies and tumor-specific research reflects the need to address these differences. Clinical trials help establish which patients may benefit, whether treatments can work alongside existing medicines and what safety concerns need attention before broader use.
Q4
How Are Top Immune Oncology Companies Advancing Treatment Innovation?
Researchers are investigating new targets and combinations that may activate complementary immune responses. Top Immune Oncology Companies explore approaches ranging from checkpoint inhibition and engineered immune cells to antibody-based treatments and methods for restoring immune signaling disrupted by tumors. Progress requires more than identifying a promising target. Researchers must establish a sound biological rationale, determine suitable dosing and assess safety and activity in clinical trials. Biomarker research can also help identify which tumors may respond to particular treatments, giving development teams a clearer basis for further investigation.
Q5
What Factors Matter When Assessing Immune Oncology Treatments?
The strength of the scientific rationale, the maturity of clinical evidence and the cancers being studied all matter when evaluating Top Immune Oncology Companies. Researchers and development partners may examine trial design, patient selection, safety findings, response durability and the feasibility of combining a candidate treatment with existing therapies. Manufacturing requirements and progress through successive clinical stages also deserve attention. Early findings can support further investigation, but they do not establish effectiveness or guarantee regulatory approval. Distinguishing promising biological activity from demonstrated patient benefit remains essential.
Q6
Why Was Stingray Therapeutics Recognized Among Top Immune Oncology Companies?
Life Sciences Review recognized Stingray Therapeutics in 2026 for its work on vizenpistat (SR-8541A), an investigational ENPP1 inhibitor intended to restore innate immune activity against cancer. The program targets a mechanism tumors use to suppress immune signaling. The company is studying vizenpistat in metastatic colorectal cancer, including liver metastases, and has reported early activity while completing eight dose levels without significant dose-limiting toxicities. It is also investigating combinations with checkpoint inhibitors, radiation, PARP inhibitors and chemotherapy. These research and development efforts provide concrete context for the recognition, although further clinical research is needed to establish the treatment's safety and effectiveness.
